Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
heart arrhythmia
Biotech
After 2020 flop, Milestone's arrhythmia spray hits in phase 3
Thirty months after failing its first phase 3, the nasal spray treatment for abnormal heart rhythm has beaten placebo in a second study.
Nick Paul Taylor
Oct 17, 2022 6:00am
How an OTC cough med could help design arrhythmia drugs
Feb 18, 2022 11:54am
Correcting heart rhythm with bacteria-derived gene therapy
Feb 7, 2022 10:00am
LQTT secures $19M to tackle heart diseases with Sanofi compounds
Aug 10, 2021 10:25am
FDA approves Abbott's Bluetooth-connected heart implants
Jul 6, 2020 10:25am
BioMarin pens gene therapy pact with little-known Swiss biotech
May 5, 2020 7:30am
